mTOR inhibition modulates vaccine-induced immune responses to generate memory T cells in patients with solid tumors
Journal for ImmunoTherapy of Cancer · 2025-03 · 13 (3) · e010408
DOI: 10.1136/jitc-2024-010408 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 25.03.2025. Verfasst von Henry G Withers und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA. Hauptthemen laut MEDLINE: Cancer Vaccines, Memory T Cells, TOR Serine-Threonine Kinases, MTOR Inhibitors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Ludwig Institute for Cancer Research, Cancer Research Institute.
Abstract (Originalsprache)
Background
Perturbation of the mechanistic target of rapamycin (mTOR) pathway can instruct effector versus memory cell fate of tumor antigen-specific T cells in preclinical models. In this study, we sought to understand the impact of rapamycin (sirolimus), an mTOR inhibitor, on reprogramming vaccine-induced T cells to enhance memory responses in patients with solid tumors following completion of their standard therapy.
Methods
We conducted three phase I clinical trials employing New York esophageal squamous cell carcinoma-1 (NY-ESO-1) vaccination approaches, with or without schedule-varied rapamycin. T cell phenotypes, functions, and Vβ usage in peripheral blood were analyzed to ask whether rapamycin influenced the generation of vaccine-induced T cells with memory attributes.
Results
The addition of rapamycin to all vaccination approaches was safe and well tolerated. Immediate (days 1–14 postvaccination) or delayed (days 15–28 postvaccination) administration of rapamycin led to a significant increase in the generation of vaccine-induced NY-ESO-1-specific T cells exhibiting central memory phenotypes (CD45RO + CD45RA − CCR7 + ). Moreover, delayed administration resulted in a greater than threefold (p=0.025) and eightfold (p=0.005) increase in the frequency of NY-ESO-1-specific CD4 + T and CD8 + T cells respectively at the time of long-term follow-up, compared with its immediate usage.
Conclusion
Our novel finding is that delayed administration of rapamycin to patients during the contraction phase of vaccine-induced antitumor immune responses was particularly effective in increasing the frequency of memory T cells up to 1 year postvaccination in patients with solid tumors. Further studies are warranted to identify the impact of this approach on the durability of clinical remission. Trial registration number NCT00803569 , NCT01536054 , NCT01522820 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
- Department of Obstetrics and Gynecology, The University of Chicago, Chicago, Illinois, USA.
- UChicago Medicine Comprehensive Cancer Center, Chicago, Illinois, USA.
- R&D, Celldex Therapeutics, Hampton, New Jersey, USA.
- Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
- Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Förderung
- NCI NIH HHS
- Ludwig Institute for Cancer Research
- Cancer Research Institute
- National Cancer Institute
Zitieren
APA
Withers, H. G., Matsuzaki, J., Long, M., Rosario, S. R., Chodon, T., Tsuji, T., Koya, R., Yan, L., Wang, J., Keler, T., Lele, S. B., Zsiros, E., Lugade, A., Hutson, A., Blank, S., Bhardwaj, N., Shrikant, P., Liu, S., & Odunsi, K. (2025). mTOR inhibition modulates vaccine-induced immune responses to generate memory T cells in patients with solid tumors. Journal for ImmunoTherapy of Cancer, 13(3), e010408. https://doi.org/10.1136/jitc-2024-010408
Vancouver
Withers HG, Matsuzaki J, Long M, Rosario SR, Chodon T, Tsuji T, et al. mTOR inhibition modulates vaccine-induced immune responses to generate memory T cells in patients with solid tumors. Journal for ImmunoTherapy of Cancer. 2025;13(3):e010408. doi:10.1136/jitc-2024-010408
BibTeX
@article{Withers2025,
author = {Withers, Henry G and Matsuzaki, Junko and Long, Mark and Rosario, Spencer R and Chodon, Thinle and Tsuji, Takemasa and Koya, Richard and Yan, Li and Wang, Jianming and Keler, Tibor and Lele, Shashikant B and Zsiros, Emese and Lugade, Amit and Hutson, Alan and Blank, Stephanie and Bhardwaj, Nina and Shrikant, Protul and Liu, Song and Odunsi, Kunle},
title = {mTOR inhibition modulates vaccine-induced immune responses to generate memory T cells in patients with solid tumors},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {3},
pages = {e010408},
doi = {10.1136/jitc-2024-010408}
}
EUVIMED